Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sapropterin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAH known ✓ | P00439 | 1/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | NOS1 | P29475 | 10/20 | 0.97 |
| ▸ | CASP7 | P55210 | 2/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.97 |
| ▸ | USP2 | O75604 | 1/20 | 0.97 |
| ▸ | NOS3 | P29474 | 3/20 | 0.61 |
| ▸ | NOS2 | P35228 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | RGS12 | O14924 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sapropterin SCHEMBL31106620 | 1.00 | KDM4E (1.00) | KDM4EMAPTBLMKMT2AALDH1A1 | |
| Sapropterin SCHEMBL29406211 | 1.00 | KDM4E (1.00) | KDM4EMAPTBLMKMT2AALDH1A1 | |
| Sapropterin SCHEMBL29059706 | 0.99 | NOS1 (1.00) | KDM4EMAPTBLMKMT2AALDH1A1 | |
| Sapropterin SCHEMBL260185 | 0.99 | NOS1 (1.00) | KDM4EMAPTBLMKMT2AALDH1A1 | |
| Sapropterin SCHEMBL29538547 | 0.99 | NOS1 (1.00) | KDM4EMAPTBLMKMT2AALDH1A1 | |
| Sapropterin SCHEMBL14072498 | 0.99 | NOS1 (1.00) | KDM4EMAPTBLMKMT2AALDH1A1 | |
| Sapropterin SCHEMBL7942378 | 0.99 | NOS1 (1.00) | KDM4EMAPTBLMKMT2AALDH1A1 | |
| Sapropterin SCHEMBL14401407 | 0.99 | NOS1 (1.00) | KDM4EMAPTBLMKMT2AALDH1A1 | |
| Sapropterin SCHEMBL21068033 | 0.99 | NOS1 (1.00) | KDM4EMAPTBLMKMT2AALDH1A1 | |
| Sapropterin SCHEMBL29351671 | 0.99 | NOS1 (1.00) | KDM4EMAPTBLMKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120142525-A | Method for detecting related substances in sapropterin hydrochloride tablet | 上海奥科达医药科技股份有限公司 | 2025-06-13 | — | — | CN | claimed |
| CN-117205164-B | Sapropterin hydrochloride tablet and preparation method thereof | 山东新时代药业有限公司 | 2024-07-26 | — | — | CN | claimed |
| CN-117205164-A | Sapropterin hydrochloride tablet and preparation method thereof | 山东新时代药业有限公司 | 2023-12-12 | — | — | CN | claimed |
| CN-109776540-B | Preparation method of sapropterin hydrochloride | 北京启慧生物医药有限公司 | 2021-07-06 | — | — | CN | claimed |
| CN-112057423-A | Granular medicine containing sapropterin hydrochloride and preparation method thereof | 兆科药业（广州）有限公司 | 2020-12-11 | — | — | CN | claimed |
| EP-3697400-A1 | METHODS OF USING EHMT2 INHIBITORS IN TREATING OR PREVENTING BLOOD DISORDERS | Epizyme, Inc. (US) | 2020-08-26 | — | — | EP | claimed |
| CN-110872293-A | Chemical synthesis and purification method of biopterin | 北京启慧生物医药有限公司 | 2020-03-10 | — | — | CN | claimed |
| CN-109776540-A | A kind of preparation method of sapropterin hydrochloride | 北京启慧医疗器械有限公司 | 2019-05-21 | — | — | CN | claimed |
| WO-2019079607-A1 | METHODS OF USING EHMT2 INHIBITORS IN TREATING OR PREVENTING BLOOD DISORDERS | Epizyme, Inc. (US) | 2019-04-25 | — | — | WO | claimed |
| CN-104257623-A | Effervescent tablet containing sapropterin dihydrochloride | GUANGDONG ZHONGSHENG PHARMACEUTICAL RES INST CO LTD | 2015-01-07 | — | — | CN | claimed |
| US-20090270619-A1 | METHOD FOR PRODUCING ALPHA FORM CRYSTALS OF SAPROPTERIN HYDROCHLORIDE | SHIRATORI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-29 | — | — | US | claimed |
| EP-1869048-B8 | METHOD FOR PRODUCING ALPHA FORM CRYSTALS OF SAPROPTERIN HYDROCHLORIDE | SHIRATORI PHARM (JP) | 2009-04-15 | — | — | EP | claimed |
| EP-1869048-B1 | METHOD FOR PRODUCING ALPHA FORM CRYSTALS OF SAPROPTERIN HYDROCHLORIDE | SHIRATORI PHARM (JP) | 2008-11-26 | — | — | EP | claimed |
| EP-1964566-A1 | PREPARATION WITH IMPROVED BIOABSORBABILITY OF SAPROPTERIN HYDROCHLORIDE | Asubio Pharma Co., Ltd. (JP) | 2008-09-03 | — | — | EP | claimed |
| US-20080207624-A1 | Therapeutic Agent for Bh4-Responsive Hyperphenylalaninemia | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-08-28 | — | — | US | claimed |
| CN-101160310-A | Method for producing alpha form crystals of sapropterin hydrochloride | SHIRATORI PHARM (JP) | 2008-04-09 | — | — | CN | claimed |
| EP-1869048-A1 | METHOD FOR PRODUCING ALPHA FORM CRYSTALS OF SAPROPTERIN HYDROCHLORIDE | Shiratori Pharmaceutical Co., Ltd. (JP) | 2007-12-26 | — | — | EP | claimed |
| EP-1757293-A1 | BH4-RESPONSIVE HYPERPHENYLALANINEMIA REMEDIES | Daiichi Asubio Pharma Co., Ltd. (JP) | 2007-02-28 | — | — | EP | claimed |
| WO-2006112495-A1 | METHOD FOR PRODUCING ALPHA FORM CRYSTALS OF SAPROPTERIN HYDROCHLORIDE | SHIRATORI PHARMACEUTICAL CO., LTD. (JP) | 2006-10-26 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |